Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CytomX Acquires Agensys’ CD3-based Bispecific Technologies | Contract Pharma

What are you searching for?

Sign in
Breaking News

CytomX Acquires Agensys’ CD3-based Bispecific Technologies

Transaction provides novel payloads and CD3 binding moieties for next wave of potent anti-cancer agents

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CytomX Therapeutics, Inc. has acquired drug conjugate linker-toxin and CD3-based bispecific technologies from Agensys, Inc., an affiliate of Astellas Pharma Inc. CytomX will pay Astellas a one-time, up-front payment.   

“The clinical progress we reported throughout 2018 provided initial proof of concept for our Probody therapeutic platform. This transaction with Astellas provides us with novel payloads and CD3 binding moieties for our next wave of potent anti-cancer agents that leverage our technology, including Probody drug conjugates and Probody T cell engaging bispecifics,” said W. Michael Kavanaugh, M.D. chief scientific officer and head of research and non-clinical development at CytomX.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics